Medullary thyroid cancer treated by capecitabine.
Medullary thyroid carcinoma with distant metastases is generally incurable, with 20% overall survival at 10 years. The treatment goal is palliative. Chemotherapy has a limited role, with low response rates and high toxicities with the different regimens. Here, we report the case of 64-year-old man with metastatic medullary thyroid carcinoma in progression after primary treatment with cisplatin-doxorubicin. The patient received capecitabine 2000 mg/m total per day x 14 days followed by 1-week rest. He received 41 cycles, and presented prolonged and objective tumor response (30 months), without any toxicity.
Labidi
Sana Intidhar
SI
Department of Medical Oncology, Institut Paoli Calmettes, 232 Boulevard Sainte Marguerite, 13009 Marseille, France. labidi@lyon.fnclcc.fr
Gravis
Gwenaelle
G
Tarpin
Carole
C
Brun
Vincent
V
Viens
Patrice
P
D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000069287:Capecitabine; D018276:Carcinoma, Medullary / Q000188:drug therapy*; D002945:Cisplatin / Q000627:therapeutic use; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005472:Fluorouracil / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010166:Palliative Care; D013964:Thyroid Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D003841:Deoxycytidine; D000069287:Capecitabine; D004317:Doxorubicin; D002945:Cisplatin; D005472:Fluorouracil